Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults with Coronavirus Disease 2019

Among adults at risk for severe coronavirus disease 2019 (COVID-19), the lowest hospitalization rate was among those who received nirmatrelvir-ritonavir after 3 or more messenger RNA vaccine doses (adjusted hazard ratio, 0.22; 95% confidence interval, .19-.24). Eligible adults, including those previously vaccinated, should be considered for COVID-19 antiviral treatment. Graphical Abstract This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/combined-protection-of-vaccination-and-nirmatrelvir-ritonavir-against-hospitalization-in-adults-with-covid-19